Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05267470 · ClinicalTrials.gov registry record · Phase 1
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT05267470 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 74 participants.
The verdict
NCT05267470, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the safety and tolerability of bemarituzumab monotherapy and combination with other anti-cancer therapies, and to determine the recommended phase 3 dose of bemarituzumab in combination with other anti-cancer therapies.
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Bemarituzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2024-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05267470
The ClinicalTrials.gov registry entry for NCT05267470 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05267470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05267470 about?
NCT05267470 is a clinical study titled "A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)". The primary objectives of this study are to evaluate the safety and tolerability of bemarituzumab monotherapy and combination with other anti-cancer therapies, and to determine the recommended phase 3 dose of bemarituzumab in combination with other anti-cancer therapies.
What is the current status of trial NCT05267470?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2022-03-29. Estimated completion is 2024-05-28.
What interventions are being tested in trial NCT05267470?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), Bemarituzumab (DRUG).
Who is sponsoring clinical trial NCT05267470?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.